Published in Blood Weekly, May 26th, 2005
"Hemopoietic stem cell transplants (HSCT) cure increasing numbers of primary immunodeficiencies (PID): residual recipient T-cell function increases risk of incomplete or decreasing immune reconstitution, which may resolve following a second, unconditioned, infusion from the same donor (boost infusion).
"We assessed the outcome of 20 boost infusions in 19/139 patients transplanted for PID patients at our center since 1987. Boost infusion was given 64-1226 days after the original HSCT. Follow-up was 4-124 months,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.